Dr. Steven J. Klein, MD
Rheumatology (Rheumatology Physician)
- Medicare participating
At a glance
- Years since graduation
- 40
- In the NPI registry since
- 2005
- Medicare patients seen, 2024
- 978
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2005Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Rheumatology Physician primary
MD license D0045175
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Berkeley Medical Center Martinsburg, WV
- Jefferson Medical Center Ranson, WV
Medical groups
- Meritus Medical Center Inc (743 clinicians)
- Klein and Associates MD PA (4 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 978
- Services billed
- 184,872
- Patients’ average age
- 74
| Service | Times | Patients |
|---|---|---|
| Injection, certolizumab pegol, 1 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered) | 60,400 | 28 |
| Injection, tocilizumab, 1 mg | 37,560 | 12 |
| Injection, denosumab, 1 mg | 28,620 | 367 |
| Injection, abatacept, 10 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered) | 28,425 | 56 |
| Injection, infliximab, excludes biosimilar, 10 mg | 9,870 | 41 |
| Injection, golimumab, 1 mg, for intravenous use | 9,350 | 13 |
| Injection, romosozumab-aqqg, 1 mg | 7,980 | 13 |
| Established patient office or other outpatient visit, 30-39 minutes | 1,161 | 762 |
| Injection of drug or substance under skin or into muscle | 1,040 | 443 |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 538 | 175 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Methotrexate (methotrexate sodium) Other prescribers in Hagerstown, MD | 78 |
| Prednisone Other prescribers in Hagerstown, MD | 78 |
| Hydroxychloroquine Sulfate Other prescribers in Hagerstown, MD | 57 |
| Folic Acid Other prescribers in Hagerstown, MD | 16 |
| Celecoxib Other prescribers in Hagerstown, MD | 15 |
| Ibuprofen Other prescribers in Hagerstown, MD | 15 |
| Colchicine Other prescribers in Hagerstown, MD | 12 |
| Leflunomide Other prescribers in Hagerstown, MD | 11 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 9 companies reported 50 payments worth $1,318 in total to this clinician.
| Amgen Inc. | $451 |
|---|---|
| AbbVie Inc. | $351 |
| AstraZeneca Pharmaceuticals LP | $223 |
| GlaxoSmithKline, LLC. | $99.70 |
| Janssen Biotech, Inc. | $94.99 |
| UCB, Inc. | $46.61 |
| Boston Scientific Corporation | $23.38 |
| Genentech USA, Inc. | $15.04 |
| Food and Beverage | $1,223 |
|---|---|
| Education | $94.99 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Janssen Biotech, Inc. Sep 3, 2025 | Education TREMFYA · Immunology · in-kind | $94.99 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 9 industry-funded studies in 2025, from 3 companies. The companies reported $122,448 in research payments for these studies, mostly to the institutions running them.
- Ixekizumab Concomitantly Administered With Tirzepatide in Adults With Psoriatic Arthritis and Obesity or Overweight
Eli Lilly and Company · Completed · NCT06588296 - A Study of Baricitinib in Participants With Rheumatoid Arthritis
Eli Lilly and Company · Completed · NCT04086745 - Study of Targeted Therapies for the Treatment of Adult Participants With Active Psoriatic Arthritis
AbbVie Inc. · Recruiting · NCT06865105 - A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis Including Those Who Have a History of Inadequate Response or Intolerance to Biologic Therapy(Ies)
AbbVie Inc. · Active, not recruiting · NCT03671148 - M15-998 - A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis Including Those Who Have a History of Inadequate Response or Intolerance to Biologic Therapy(Ies)
AbbVie Inc. - A Randomized, Parallel-group, Double-blind, Placebo-controlled, Multicenter Phase III Trial to Evaluate Efficacy and Safety of Secukinumab Administered Subcutaneously Versus Placebo, in Combination With a Glucocortico…
Novartis Pharmaceuticals Corporation - An Open-label, Multi-center Protocol for Patients Who Have Completed a Previous Novartis Sponsored Secukinumab Study and Are Judged by the Investigator to Benefit From Continued Secukinumab Treatment
Novartis Pharmaceuticals Corporation - A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis Including Those Who Have a History of Inadequate Response or Intolerance to Biologic Therapy(Ies)
AbbVie Inc. - M15-572 - A Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Participants With Psoriatic Arthritis Who Have an Inadequate Response to at Least One Non-Biologic Disease Modifying Anti-Rheumatic Dr…
AbbVie Inc.
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.